[18F]Fluorothymidine (FLT) PET/CT Imaging In Rb+ Metastatic Breast Cancer Patients Undergoing LEE011 And Weekly Paclitaxel Therapy

  • STATUS
    Recruiting
  • participants needed
    20
  • sponsor
    Abramson Cancer Center of the University of Pennsylvania
Send
Updated on 8 November 2020
See if I qualify
paclitaxel
advanced breast cancer
HER2
erbb2

Summary

Patients with a history of metastatic breast cancer who are candidates for participation in the companion therapeutic trial, UPCC 06115 "A Phase I Trial of Ribociclib (LEE011) and Weekly Paclitaxel in Patients with Rb+ Advanced Breast Cancer" may be candidates for this imaging study. Patients may participate in this study if they are at least 18 years of age, most participants will be receiving care at the clinical practices of the University of Pennsylvania. Patients that meet the eligibility criteria will be approached about study participation regardless of race or ethnic background.

The investigators anticipate enrolling up to 20 participants with metastatic breast cancer who meet eligibility requirements for this study and for the companion therapy trial UPCC 06115 "A Phase I Trial of Ribociclib (LEE011) and Weekly Paclitaxel in Patients with Rb+ Advanced Breast Cancer", Accrual will likely occur over approximately 4 years.

Positron emission tomography (PET/CT) imaging will be used to evaluate proliferative activity in sites of metastatic disease using the investigational radiotracer [18F]fluorothymidine (FLT). Imaging will occur prior to starting therapy on the separate therapeutic protocol UPCC 06115. Patients may undergo a second FLT PET/CT scan following a 3-day run of ribociclib (LEE011) (day -6 to -4) on Day -3 ( 1 day) and a third FLT PET/CT scan on cycle 1 day 1 (-1 day) before starting treatment with Paclitaxel to compare changes in FLT uptake measures.

Details
Condition Breast Cancer
Treatment Paclitaxel, [18F]FLT PET/CT
Clinical Study IdentifierNCT02774473
SponsorAbramson Cancer Center of the University of Pennsylvania
Last Modified on8 November 2020

Eligibility

 Yes No Not Sure

Inclusion Criteria

At least 18 years of age
History of histologically or cytologically confirmed breast cancer, any ER, PR or HER2 status is allowed as long as it expresses the Rb protein
At least one site of metastatic breast cancer that is outside of the liver and bone that is identified by standard imaging (e.g. CT, MRI, FDG PET/CT, ultrasound, x-ray) and is measurable as defined by RECIST 1.1
Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures
Patients must be candidates to receive treatment on the therapeutic trial UPCC06115, a Phase I study of ribociclib (LEE011) and weekly paclitaxel

Exclusion Criteria

Females who are pregnant at the time of screening will not be eligible for this study, urine pregnancy test will be performed at screening in women of child-bearing potential
Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
Serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study
Ineligible for the therapeutic trial UPCC 06115 Only individuals (aged 18 or over) who can understand and give informed consent will be eligible to participate in this study. Individuals who are considered to be mentally disabled will not be recruited for this study. All subjects must be able to give informed consent. We will not be using specific methods to assess decisional capacity. Economically disadvantaged persons will not be vulnerable to undue influence, patients will be informed that participation is voluntary. All individuals will be told that their choice regarding study participation will in no way change their access to clinical care. This should negate any undue influence or coercion. Children, fetuses, neonates, or prisoners are not included in this research study. It is unlikely that the researchers will encounter a patient/study participant who is pregnant during enrollment because pregnant patients may not enroll on the parent treatment protocol, UPCC06115. However, menopausal status of the study participant will be reviewed during the screening process by examining the patient's medical record; women of child-bearing potential will have a urine pregnancy test at the time of screening
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

paclitaxel
advanced breast cancer
HER2
erbb2

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note